Stem Cell and Regulatory T Cell Composition for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, including immunosuppressants and stem cell therapies, face challenges such as low persistence of effects, side effects, and limited ability to shift Th2 responses to Th1 in patients, necessitating a more effective therapeutic approach.
Innovation Solution
A composition and kit using stem cells primed with TNF-α, IFN-γ, and IFN-α, or TNF-α, IFN-γ, IFN-α, and vitamins, combined with regulatory T cells, to enhance immunomodulatory and anti-inflammatory functions, thereby alleviating immune imbalance and treating atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressants are used to treat atopic dermatitis, then anti-inflammatory effect is improved, but side effects such as nephrotoxicity and hypertension increase
Solution Approach 1:
The patent extracts and utilizes specific immunomodulatory cells (regulatory T cells and stem cells) that provide anti-inflammatory effects without the harmful side effects of conventional immunosuppressants. This selective extraction of beneficial immune components resolves the contradiction between therapeutic effect and safety.
Solution Approach 2:
The patent introduces regulatory T cells and stem cells as intermediary agents that mediate immune modulation. These cells act as biological intermediaries that suppress inflammation through natural mechanisms rather than direct pharmacological suppression, avoiding the harmful effects of traditional immunosuppressants.
2Object-affected harmful factors
If stem cell therapy is used to treat atopic dermatitis, then safety is improved, but persistence of effects and in vivo survival rates are low
Solution Approach 1:
The patent merges two types of cells with complementary functions: regulatory T cells (which provide immunomodulatory effects) and stem cells (which provide safety and regenerative capacity). This combination synergistically improves both the persistence of therapeutic effects and safety, resolving the contradiction between safety and duration of action.
Solution Approach 2:
The patent performs preliminary expansion and activation of regulatory T cells and stem cells ex vivo before administration. This preliminary action enhances the functional capacity and survival potential of the cells, thereby improving persistence of effects while maintaining safety.
3Ease of operation
If conventional therapies are used for atopic dermatitis, then treatment is simple, but ability to shift Th2 responses to Th1 is limited
Solution Approach 1:
The patent utilizes the inherent ability of regulatory T cells and stem cells to self-modulate immune responses. These cells naturally promote Th1 differentiation and suppress Th2 responses through their biological functions, achieving reliable immune response modulation without complex external intervention while maintaining relatively simple administration.
Data Source
AI summary
The present invention relates to: a composition and a kit for preventing, alleviating or treating atopic dermatitis, comprising primed function-enhanced stem cells and regulatory T cells; and a method for preventing, alleviating or treating atopic dermatitis by using same. When function-enhanced stem cells, of the present invention, treated with TNF-α, IFN-γ and IFN-α or TNF-α, IFN-γ, IFN-α and vitamins are treated in combination with regulatory T cells, the imbalance of Th1/Th2 cells of an atopic dermatitis patient can be alleviated and the status of the atopic dermatitis patient can be shifted to Th1, and thus the present invention can be widely used in various fields of prevention, alleviation or treatment of atopic dermatitis.